Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]ABT-199 in Relapsed/Refractory NHL
NCT02095574Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in Non-Hodgkin lymphoma (NHL), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration at 9 days, Time to Cmax at 9 days and 1 more. Planned start Sep 2014; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02095574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095574.